- Published at
- by seekingalpha.com
positive
positive
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us (OMER)
Omeros Corporation's stock surges as narsoplimab data shows 68% lower death risk in HSCT-TMA patients. Click to learn about the potential and risks of OMER stock.